Related Experiment Video
Updated: Aug 2, 2025
08:50
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
795
Engineering Extracellular Vesicles as Delivery Systems in Therapeutic Applications
Liwei Wang1,2,3,4, Di Wang1,2,3,4, Zhaoming Ye1,2,3,4
1Department of Orthopedic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310009, P. R. China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|April 20, 2023
Summary
Extracellular vesicles (EVs) are natural nanocarriers that act as cell messengers for intercellular communication. This review details engineering EVs for therapeutic delivery across various diseases, highlighting challenges and strategies.
Area of Science:
- Biotechnology
- Nanomedicine
- Cell Biology
Background:
- Extracellular vesicles (EVs) are secreted by cells, mediating intercellular communication in health and disease.
- EVs function as natural nanocarriers, capable of delivering therapeutic biomolecules.
- Their role in intercellular and inter-organismal communication is increasingly recognized.
Purpose of the Study:
- To review the engineering of extracellular vesicles (EVs) for therapeutic applications.
- To summarize recent progress in EV-based delivery systems for various diseases.
- To identify challenges and propose strategies for EV-based therapies.
Main Methods:
- Review of literature on EV sources, isolation, cargo loading, and targeting strategies.
- Summary of current applications of engineered EVs in disease treatment.
- Analysis of obstacles and future directions in EV-based therapeutic development.
Main Results:
- Detailed description of methods for engineering EVs, including source selection, isolation techniques, cargo loading, and targeting modifications.
- Comprehensive overview of EV-based delivery system applications in cancer, cardiovascular, liver, kidney, and nervous system diseases, as well as COVID-19.
- Identification of key challenges in current EV-based therapies, such as scalability, stability, and immunogenicity.
Conclusions:
- Engineered EVs show significant promise as versatile nanocarriers for targeted drug delivery.
- Further research and development are crucial to overcome existing challenges and realize the full therapeutic potential of EVs.
- Strategic approaches are needed to advance EV-based therapies from preclinical studies to clinical practice.
